To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Pomalidomide
Related studies linked through entity extraction aliases.
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- PHASE3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- Status
- RECRUITING
- Phase
- PHASE3
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
- Status
- RECRUITING
- Phase
- NA
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Status
- WITHDRAWN
- Phase
- PHASE3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Status
- RECRUITING
- Phase
- PHASE3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Status
- RECRUITING
- Phase
- PHASE3
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
- Status
- RECRUITING
- Phase
- NA
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2